AZN stock icon

AstraZeneca
AZN

$79.24
1.6%
 

About: A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its revenue.

Employees: 89,900

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 5 analysts
0
News positive %
of 31 articles

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

43% more repeat investments, than reductions

Existing positions increased: 468 | Existing positions reduced: 327

3% more first-time investments, than exits

New positions opened: 119 | Existing positions closed: 116

2% more call options, than puts

Call options by funds: $480M | Put options by funds: $470M

1% more capital invested

Capital invested by funds: $32.9B [Q4 2023] → $33.1B (+$236M) [Q1 2024]

0% more funds holding

Funds holding: 1,097 [Q4 2023] → 1,100 (+3) [Q1 2024]

0% more ownership

Funds ownership: 31.48% [Q4 2023] → 31.49% (+0%) [Q1 2024]

15% less funds holding in top 10

Funds holding in top 10: 13 [Q4 2023] → 11 (-2) [Q1 2024]

Research analyst outlook

5 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$80
1%
upside
Avg. target
$86
8%
upside
High target
$97
22%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
Argus Research
Jasper Hellweg
7%upside
$85
Buy
Maintained
30 May 2024
Goldman Sachs
Rajan Sharma
22%upside
$97
Buy
Initiated
30 May 2024
BMO Capital
Etzer Darout
3%upside
$82
Outperform
Maintained
26 Apr 2024
BMO Capital
Etzer Darout
1%upside
$80
Outperform
Maintained
12 Feb 2024
Morgan Stanley
Mark Purcell
7%upside
$85
Overweight
Initiated
23 Jan 2024

Financial journalist opinion

Based on 31 articles about AZN published over the past 30 days